(Q38970911)

8 September 2017

Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib (English)

1 reference

8 September 2017

0 references

1 reference

Astrid Drenckhan

1

1 reference

8 September 2017

Tobias Grob

2

1 reference

8 September 2017

Anna Dupree

3

1 reference

8 September 2017

Thorsten Dohrmann

4

1 reference

8 September 2017

Oliver Mann

5

1 reference

8 September 2017

Jakob R Izbicki

6

1 reference

8 September 2017

Stephanie J Gros

7

1 reference

8 September 2017

language of work or name

English

0 references

publication date

29 July 2014

1 reference

Langenbeck's Archives of Surgery

8 September 2017

1 reference

8 September 2017

399

1 reference

8 September 2017

879-888

1 reference

8 September 2017

7

1 reference

describes a project that uses

8 September 2017

0 references

0 references

0 references

0 references

https://scigraph.springernature.com/pub.10.1007/s00423-014-1235-1

0 references

cites work

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Epidermal growth factor receptor-directed therapy in esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

21 January 2018

Oesophageal carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Esophageal carcinoma: are modern targeted therapies shaking the rock?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly metastatic orthotopic model of esophageal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Oesophagogastric junction adenocarcinoma: which therapeutic approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Amplification and over-expression of theEGFR anderbB-2 genes in human esophageal adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00423-014-1235-1

Is FISH floating or still swimming in the lung cancer ocean?

21 January 2018

1 reference

12 December 2020

Complementary use of fluorescence and magnetic resonance imaging of metastatic esophageal cancer in a novel orthotopic mouse model

1 reference

12 December 2020

Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia.

1 reference

12 December 2020

Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer

1 reference

12 December 2020

Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy

1 reference

12 December 2020

Tumorigenic potential of apparently tumor-free lymph nodes

1 reference

12 December 2020

Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer

1 reference

12 December 2020

Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.

1 reference

12 December 2020

Clinical significance of p53 alterations in surgically treated prostate cancers

1 reference

12 December 2020

Gains and Amplifications of c-myc, EGFR, and 20.q13 Loci in the No Dysplasia-Dysplasia-Adenocarcinoma Sequence of Barrett's Esophagus

1 reference

12 December 2020

Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus

1 reference

12 December 2020

Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome

1 reference

12 December 2020

Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.

1 reference

12 December 2020

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer

1 reference

12 December 2020

Epidermal growth factor expression in esophageal adenocarcinoma: a clinically relevant target?

1 reference

12 December 2020

10.1007/S00423-014-1235-1

Identifiers

DOI

1 reference

8 September 2017

1 reference